Abivax Reports Outcomes of Annual General Meeting

On June 11, 2025, Abivax SA, a biotechnology firm specializing in therapies for chronic inflammatory diseases, disclosed the results of its Annual General Meeting, held on June 6, 2025, in Paris. The meeting was chaired by Sylvie Grégoire, Chairman of the Board of Directors.

All resolutions presented by the Board were approved, including the financial statements of 2024, the compensation policies for key executives, and financial transaction delegations. Additionally, shareholders ratified the appointments of Sylvie Grégoire as Chairman and Dominik Höchli, MD, as a Board member.

Detailed voting results can be accessed on Abivax's website. The company remains focused on its lead candidate, obefazimod, currently in Phase 3 trials for ulcerative colitis. For more, visit www.abivax.com.